Online inquiry

IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6280MR)

This product GTTS-WQ6280MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), T cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6280MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12891MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ3561MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ10659MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ10555MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ14356MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ7269MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ13627MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ1317MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW